clinical trial · NCT03268382
p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
High-grade Serous Ovarian CancerAPR-246Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
brief summary
The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and PLD chemotherapy regimen in patients with platinum-resistant recurrent high grade serous ovarian cancer (HGSOC) with mutated TP53. In addition, the study aims to assess the safety profile of the combined APR-246 and PLD chemotherapy regimen, to evaluate potential biomarkers, and to assess the biological activity in tumor and surrogate tissues. The trial will enroll at least 25 evaluable patients.
started
Jul 31, 2017
primary completion
Jul 10, 2019
completion
Jul 10, 2019
last updated
Mar 17, 2025
official title
PiSARRO-R: p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol